Efficacy and safety of G-CSF prophylaxis in patients with extensive-stage small cell lung cancer receiving chemoimmunotherapy.

Autor: Ilhan Y; Department of Medical Oncology, Antalya City Hospital, Antalya, Turkey., Ucar G; Department of Medical Oncology, Ankara Bilkent City Hospital, Ankara, Turkey., Baser MN; Department of Medical Oncology, Adnan Menderes University, Aydın, Turkey., Guzel HG; Antalya Education and Research Hospital, Department of Medical Oncology, Health Sciences University, Antalya, Turkey., Efil SC; Department of Medical Oncology, Ankara Bilkent City Hospital, Ankara, Turkey., Demir B; Department of Medical Oncology, Adnan Menderes University, Aydın, Turkey., Ercan Uzundal D; Faculty of Medicine, Department of Medical Oncology, Gazi University, Ankara, Turkey., Karacelik T; Faculty of Medicine, Department of Medical Oncology, Necmettin Erbakan University, Konya, Turkey., Sever N; Faculty of Medicine, Department of Medical Oncology, Marmara University, Istanbul, Turkey., Balcik OY; Department of Medical Oncology, Mardin Training and Research Hospital, Mardin, Turkey., Arvas H; Faculty of Medicine, Department of Medical Oncology, Dicle University, Diyarbakır, Turkey., Karadag I; Erol Olcok Education and Research Hospital, Department of Medical Oncology, Hitit University, Corum, Turkey., Kadioglu A; Department of Medical Oncology, University of Health Sciences, Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Turkey., Ekinci ÖB; Department of Medical Oncology, Cemil Tascioglu City Hospital, Istanbul, Turkey., Karacin C; Department of Medical Oncology, University of Health Sciences, Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Turkey., Urakci Z; Faculty of Medicine, Department of Medical Oncology, Dicle University, Diyarbakır, Turkey., Kostek O; Faculty of Medicine, Department of Medical Oncology, Marmara University, Istanbul, Turkey., Karakurt Eryilmaz M; Faculty of Medicine, Department of Medical Oncology, Necmettin Erbakan University, Konya, Turkey., Yazici O; Faculty of Medicine, Department of Medical Oncology, Gazi University, Ankara, Turkey., Sendur MAN; Department of Medical Oncology, Ankara Bilkent City Hospital, Ankara, Turkey., Ozturk B; Antalya Education and Research Hospital, Department of Medical Oncology, Health Sciences University, Antalya, Turkey., Uncu D; Department of Medical Oncology, Ankara Bilkent City Hospital, Ankara, Turkey., Ergun Y; Department of Medical Oncology, Antalya City Hospital, Antalya, Turkey.
Jazyk: angličtina
Zdroj: Expert opinion on pharmacotherapy [Expert Opin Pharmacother] 2024 Aug; Vol. 25 (11), pp. 1555-1563. Date of Electronic Publication: 2024 Aug 11.
DOI: 10.1080/14656566.2024.2391007
Abstrakt: Objectives: We aimed to evaluate the efficacy and safety of granulocyte-colony stimulating factor (G-CSF) prophylaxis during chemoimmunotherapy with carboplatin plus etoposide and atezolizumab in extensive-stage small cell lung cancer (ES-SCLC).
Methods: This retrospective, multicenter study enrolled ES-SCLC patients receiving carboplatin plus etoposide and atezolizumab, categorized into G-CSF and non-G-CSF groups. Demographic and disease-related data were collected. Response rates, progression-free survival (PFS), overall survival (OS), and toxicity were analyzed.
Results: Of 119 patients (median age: 63 years), the overall response rate (ORR) and disease control rate (DCR) were 72.3% and 81.5%, respectively. In the G-CSF group, the ORR was 76.4% compared to 60.0% in the non-G-CSF group ( p  = 0.33), and the DCR was 85.4% versus 70.0%, respectively ( p  = 0.46). Median PFS was 8.3 months (95% CI, 6.8-9.8) in the G-CSF group and 6.8 months (95% CI, 6.2-7.5) in the non-G-CSF group ( p  = 0.24). Median OS was 13.8 months (95% CI, 9.6-18.1) for the G-CSF group and 10.6 months (95% CI, 7.9-13.3) for the non-G-CSF group ( p  = 0.47). Grade 3 ≥ adverse events were similar between groups (49.4% vs. 33.3%, respectively, p  = 0.12).
Conclusion: G-CSF prophylaxis can be safely used in ES-SCLC patients undergoing carboplatin plus etoposide and atezolizumab regimen without significantly altering efficacy or increasing toxicity.
Databáze: MEDLINE
Externí odkaz: